Full Press Release Details
CHAMPIONS Biotechnology, Inc.
Boulevard, Suite 102-316
Arlington, VA 22201, USA
Champions Biotechnology, Inc. acquires rights to cancer drug
Arlington, VA., February 14, 2007. Champions Biotechnology, Inc. (OTC Bulletin
Board: CSBR), a development stage biotechnology company, announced today
the acquisition of patent rights encompassing two
Benzoylphenylurea (BPU) sulfur analog compounds that have shown promising
potent activity against prostate and pancreatic cancer cell lines (Journal of
Medicinal Chemistry, 2006, Vol. 49, No.7, 2357-2360). The acquired
rights include pending U.S. Patent Application no. 11/673,519 and
corresponding international patent application (PCT/US2006/014449) filed
under the Patent Cooperation Treaty (PCT), both entitled Design and Synthesis of
Novel Tubulin Polymerization Inhibitors: Benzoylphenylurea (BPU) Sulfur
These antimitotic inhibitors target MAPT (Microtubule-Associated Protein Tau)
deficient tumors, a common feature of solid tumors, and have performed better
than Docetaxel (Taxotere) in the difficult to treat direct patient xenograft
models of pancreatic cancer (Journal of the National Cancer Institute,
Vol. 99, Issue 2, January 17 2007, 105-107). The Company, in exchange for
550,000 restricted shares of its common stock, was assigned all the rights in
the U.S. and in foreign countries to the applications for these inhibitors
developed at Johns Hopkins University by their inventors Drs. Saeed Khan,
Gurulingappa Hallur, Manuel Hidalgo and Antonio Jimeno.
This acquisition is the Company's initial step in building a biotechnology
company from the ground up with a future portfolio of possible therapeutic drug
candidates among other ventures that it is actively exploring. The Company plans
to develop candidates from its portfolio of therapeutic compounds and partner
with pharmaceutical and/or biotechnology partners for development, regulatory
approval and marketing as appropriate.
This press release contains "forward-looking statements" (within the meaning of
the Private Securities Litigation Act of 1995) that inherently involve risk and
uncertainties. The Company generally uses words such as "believe," "may,"
"could," "will," "intend," "expect," "anticipate," "plan," and similar
expressions to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company's actual results
could differ materially from those anticipated in the forward-looking statements
for many unforeseen factors, which may include, but are not limited to, changes
in general economic conditions, the ongoing threat of terrorism, ability to have
access to financing sources on reasonable terms and other risks that are
described in this document. Although the Company believes the expectations
reflected in the forward-looking statements are reasonable, they relate only to
events as of the date on which the statements are made, and the Company's
future results, levels of activity, performance or achievements may not meet
these expectations. The Company does not intend to update any of the
forward-looking statements after the date of this press release to conform these
statements to actual results or to changes in the Company's expectations,
except as required by law.
Contact: James Martell (703) - 526-0400